About NovaLead Pharma
NovaLead Pharma is a Healthcare company based in Pune (India) founded in 2007 by Ajay Aslekar, Girish Lakhe, Sayali Aslekar, Prerna Deshpande, Atul Aslekar, and Supreet Deshpande. It operates as a drug repurposing and discovery are enabled by a proprietary platform. NovaLead Pharma has raised $8.04 million across 4 funding rounds from investors including Tata Capital Healthcare Fund, Boxmoor Mauritius and BIRAC. NovaLead Pharma was last valued at $30.96 million in July 2015. Its chief executive is Supreet Deshpande. Its Indian entity Novalead Pharma Private Limited reported revenue of ₹16.4 Lakh. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Formulation. Its competitors include Aclaris Therapeutics, BiomX, Alumis, Elektrofi and Rani Therapeutics and 3 more; 7 of its 8 listed competitors have raised funding.
Company details
NovaLead Pharma was founded in 2007 in Pune, India, within the pharmaceutical sector. Drug repurposing and discovery services are delivered through a proprietary technology platform. Key developments include Galnobax, a topical esmolol gel for diabetic foot ulcers, and NLP91, a repurposed generic for psoriasis treatment. Operations center on biotech innovation and therapeutic applications in dermatology and wound care.
- Headquarters Pune, India
- Founders Ajay Aslekar, Girish Lakhe, Sayali Aslekar, Prerna Deshpande, Atul Aslekar, Supreet Deshpande
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website novaleadpharma.com
- Social LinkedIn X
- Legal Name Novalead Pharma Private Limited
- Date of Incorporation 31 Oct, 2007
- Jurisdiction Pune, Maharashtra, India
- Annual Revenue₹16.4 Lakh
FY 2024 · -97% YoY
- Net Loss-₹3.53 Cr
FY 2024 · -2153% margin
- EBITDA-₹3.13 Cr
FY 2024 · -1907% margin
- Total Equity Funding$8.04M (USD)
in 4 rounds
- Latest Funding Round$3.15M (USD), Series B
Jul 2015
- InvestorsTata Capital Healthcare Fund
& 2 more
Associated legal entities of NovaLead Pharma
NovaLead Pharma operates through Novalead Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Novalead Pharma Private Limited CIN U73100PN2007PTC130929 | Active | 31 Oct 2007 | Pune, Maharashtra | ₹0.2 Cr | – | 6 | View details |
Funding Insights of NovaLead Pharma
NovaLead Pharma has successfully raised a total of $8.04M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $3.15 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.04M
- Total Rounds 4
- Last Round Series B — $3.15M
- First Round $2.77M
(Aug 2010)
- Investors Count 3
All 4 funding rounds of NovaLead Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2015 | $3.15M | Series B | $30.96M | TCHF | |
| Jun 2015 | – | Grant | – | – | |
| Nov 2011 | $2.12M | Series A | $19.72M | Boxmoor Mauritius | – |
| Aug 2010 | $2.77M | Series A | $••••• | TCHF | – |
| Date | Valuation | Stage |
|---|---|---|
| Jul 2015 | $30.96M | •••••••• |
| Nov 2011 | $19.72M | •••••••• |
| Aug 2010 | $••••• | •••••••• |
Full valuation and stage history of NovaLead Pharma
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $30.96M (Jul 2015). 3 investors in total: 3 institutional.
Investors in NovaLead Pharma
NovaLead Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Tata Capital Healthcare Fund, Boxmoor Mauritius and BIRAC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity fund investing in healthcare and lifesciences in India. | 2021 | tatacapitalhealthcarefund.com | Mumbai, India | |
- | – | boxmoormauritius.tcc.mode | - | |
Business incubation services are provided across multiple sectors. | – | birac.nic.in | Delhi, India |
Investor details for NovaLead Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Novalead Pharma Private Limited (NovaLead Pharma)
Novalead Pharma Private Limited is the primary company behind NovaLead Pharma. The board of Novalead Pharma Private Limited currently have 6 directors; the longest-serving is Atul Sharad Aslekar, appointed in 2007. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Atul Sharad Aslekar DIN 00126698 | Director | 31 Oct 2007 | 18 yrs 11 mo | Novalead Pharma Private Limited |
| Supreet Deshpande Kiran DIN 00126671 | Director | 31 Oct 2007 | 18 yrs 11 mo | Novalead Pharma Private Limited |
| Sudhir Kulkarni Appaji DIN 02768943 | Director | 17 Aug 2009 | 17 yrs 2 mo | Novalead Pharma Private Limited |
| Girish Vithalrao Lakhe DIN 00335011 | Director | 17 Aug 2009 | 17 yrs 2 mo | Novalead Pharma Private Limited |
| Sankara Narayanan Sankarasubramanian DIN 03543495 | Nominee Director | 24 Nov 2022 | 3 yrs 10 mo | Novalead Pharma Private Limited |
| Vandan Girdharlal Agrawal DIN 00041252 | Nominee Director | 24 Nov 2022 | 3 yrs 10 mo | Novalead Pharma Private Limited |
People of NovaLead Pharma
6 people are tracked at NovaLead Pharma (6 in leadership).
| Name | Role | Group |
|---|---|---|
Ajay Aslekar | Co-Founder | Leadership |
| Co-Founder | Leadership | |
Sayali Aslekar | Co-Founder | Leadership |
Prerna Deshpande | Co-Founder | Leadership |
| Co-Founder & CTO | Leadership | |
| Co-Founder & CEO & Managing Director | Leadership |
Complete people profiles for NovaLead Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of NovaLead Pharma
Figures of Novalead Pharma Private Limited, the primary company behind NovaLead Pharma, for FY 2024. Revenue was ₹16.4 Lakh (-97% year on year). Net loss was -₹3.53 Cr (-2153% margin). EBITDA was -₹3.13 Cr (-1907% margin). Revenue has grown at a compounded annual rate of -49% over three years and -38% over five years.
- ₹16.4 LakhRevenue · FY 2024 · -97% YoY
- -₹3.53 CrNet loss · -2153% margin
- -₹3.13 CrEBITDA · -1907% margin
- ₹1.8 LakhPaid-up capital
- -49%Revenue CAGR, 3 years
- -38%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Novalead Pharma Private Limited are on its company page.
Detailed financial statements for NovaLead Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of NovaLead Pharma
4 dated milestones of NovaLead Pharma across 8 years, from founding to its latest funding, stage changes and deals.
- Founded NovaLead Pharma is founded.
- Funding First funding round of $2.8M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series B, of $3.2M.
Competitors of NovaLead Pharma
NovaLead Pharma has 8 listed competitors in our database, 7 of them funded. They include Aclaris Therapeutics, BiomX, Alumis, Elektrofi and Rani Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| biomx.com | 2015 | Ness Ziona, Israel | $56M | – | Microbiome therapeutics are developed for dysbiosis-linked diseases. | |
| alumis.com | 2003 | San Francisco, United States | $529M | – | Therapeutics for autoimmune diseases are developed by Alumis. | |
| elektrofi.com | 2016 | Boston, United States | $152.25M | 71 | Digital platform transforming the delivery of biologic medicines | |
| ranitherapeutics.com | 2012 | San Jose, United States | $226.49M | – | Technology for oral delivery of large drug molecules is developed. | |
| samsungbioepis.com | 2012 | Incheon, South Korea | – | – | Developer of biosimilar drugs for the treatment of multiple diseases | |
| aurealistherapeutics.com | 2015 | Basel, Switzerland | $22.04M | – | Provider of cell & gene therapy platforms for chronic wounds, cancer, and inflammatory diseases | |
| lindybio.com | 2016 | Durham, United States | $7.26M | 4 | Formulation technology for bio-therapeutics drug delivery is developed. |
Detailed competitors of NovaLead Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NovaLead Pharma
Websites that share an audience with NovaLead Pharma (novaleadpharma.com).
Websites whose visitors overlap most with NovaLead Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.co.in | 100% | 77M | #407 | View details | |
| hipra.com | 71% | 52.5K | #601,506 | View details |
Top companies in Diabetes
10 companies that operate in the same segment as NovaLead Pharma (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 237 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novalead Pharma
Complete news archive for NovaLead Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NovaLead Pharma
NovaLead Pharma was founded in 2007 and raised its 1st funding round 3 years after it was founded.
NovaLead Pharma is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
Supreet Deshpande is the current CEO of NovaLead Pharma. They have also founded this company.
NovaLead Pharma is a funded company, having raised a total of $8.04M across 4 funding rounds to date. The company's 1st funding round was a Series A of $2.77M, raised on Aug 2010.
The primary company behind NovaLead Pharma, Novalead Pharma Private Limited, reported revenue of ₹16.4 Lakh for FY 2024, down 97% year on year.
NovaLead Pharma was founded in 2007 in Pune, India, within the pharmaceutical sector. Drug repurposing and discovery services are delivered through a proprietary technology platform. Key developments include Galnobax, a topical esmolol gel for diabetic foot ulcers, and NLP91, a repurposed generic for psoriasis treatment. Operations center on biotech innovation and therapeutic applications in dermatology and wound care.
NovaLead Pharma's top competitors include Elektrofi, Aclaris Therapeutics and Samsung Bioepis.
NovaLead Pharma has 3 investors. Key investors include Tata Capital Healthcare Fund, Boxmoor Mauritius, and BIRAC.
The valuation of NovaLead Pharma is $30.96M as of Jul 2015.
NovaLead Pharma operates through Novalead Pharma Private Limited.
The legal entities of NovaLead Pharma currently have 6 directors, including Sankara Narayanan Sankarasubramanian, Sudhir Kulkarni Appaji, Vandan Girdharlal Agrawal and others.